BFEC
SGMO

Benjamin F. Edwards & Company’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Benjamin F. Edwards & Company’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,000
Closed -$2K – 1761
2021
Q3 		$2K Buy
1,000
+600
+150% +$5.93K ﹤0.01% 1648
2021
Q2 		$2K Sell
400
-1,400
-78% -$15.9K ﹤0.01% 1639
2021
Q1 		$2K Buy
1,800
+1,000
+125% +$13.5K ﹤0.01% 1631
2020
Q4 		$5K Buy
+800
New +$9.37K ﹤0.01% 1414

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Benjamin F. Edwards & Company's SGMO Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 35% in Q2 2024, buying an estimated $162 and bringing the position to 1,150 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2227.

Benjamin F. Edwards & Company first reported a position in SGMO in Q1 2019 and has held it in 22 quarters since. The position peaked at $37K in Q4 2020. 129 funds tracked by Wall St. Rank hold SGMO as of Q2 2024.

  • Benjamin F. Edwards & Company held 1,150 shares of SANGAMO THERAPEUTICS INC worth $0 as of Q2 2024.
  • Benjamin F. Edwards & Company bought 300 SANGAMO THERAPEUTICS INC shares in Q2 2024, an estimated $162.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #2227 holding.
  • Benjamin F. Edwards & Company first reported a position in SANGAMO THERAPEUTICS INC in Q1 2019 and has held it in 22 quarters since.
  • Benjamin F. Edwards & Company's SANGAMO THERAPEUTICS INC position peaked at $37K in Q4 2020.
  • 129 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.